Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2Fhealthify-logo.png){kind=logo}
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2Fribometrix.png)
SV Health Investors Promotes Greg Madden to Managing Partner
Merck KGaA and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FAeroCare-logo.png){kind=logo}
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FLOGOJPGsCatamaran_rgb.jpg)
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FCentauri-logo.png){kind=logo}
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FLOGOJPGsCatamaran_rgb.jpg)
23 November 2020Portfolio NewsCatamaran Bio Launches with $42 Million Financing to Develop Off-the-Shelf CAR-NK Cell Therapies to Treat Solid Tumors
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FXilio-logo.png)
10 November 2020Portfolio NewsXilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FAlchemab-logo.png)
29 September 2020Portfolio NewsAlchemab partners with Amii to accelerate the development of novel therapeutics to cure disease- 18 September 2020SV NewsSV Health Investors welcomes six new Venture Partners to the Biotech team
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FCellinta.PNG)
15 September 2020Portfolio NewsSV Health Investors announces launch of biotech portfolio company, Cellinta and the Company’s appointment of Dr Soraya Bekkali as CEO
:no_upscale()/svhi.fra1.digitaloceanspaces.com%2FBadamchi-Zadeh-Alex-4.jpg)
7 September 2020SV NewsSV Health Investors (SV) announces the appointment of Alex Badamchi-Zadeh PhD, strengthening their transatlantic Biotech team- 23 July 2020Portfolio NewsXilio Therapeutics Appoints Paul J. Clancy to its Board of Directors
- 20 July 2020SV NewsBritish Patient Capital commits $65m to SV Health Investors, to invest in life-changing biotechnology companies
:no_upscale():fill(white)/svhi.fra1.digitaloceanspaces.com%2Flogos%2FAlchemab-logo.png)
23 June 2020Portfolio NewsAlchemab Therapeutics among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK- 17 June 2020Portfolio NewsXilio Therapeutics Appoints Daniel S. Lynch as Chair of Board of Directors
- 27 April 2020Portfolio NewsXilio Therapeutics Appoints Martin H. Huber, M.D. as Chief Medical Officer to lead XTX201 (tumor-selective IL-2) and XTX101 (tumor-Selective aCTLA-4) into the clinic while xilio continues to advance its tumor-selective cytokine pipeline